Susquehanna International Group’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.21M | Sell |
60,281
-35,284
| -37% | -$5.41M | ﹤0.01% | 3238 |
|
|
2025
Q4 | $13.2M | Buy |
95,565
+89,201
| +1,402% | +$11.7M | ﹤0.01% | 2699 |
|
|
2025
Q3 | $816K | Buy |
6,364
+1,290
| +25% | +$157K | ﹤0.01% | 7826 |
|
|
2025
Q2 | $614K | Sell |
5,074
-282,612
| -98% | -$31.9M | ﹤0.01% | 8694 |
|
|
2025
Q1 | $32.1M | Sell |
287,686
-43,136
| -13% | -$4.59M | 0.01% | 1327 |
|
|
2024
Q4 | $32.2M | Buy |
330,822
+271,419
| +457% | +$28.9M | ﹤0.01% | 1461 |
|
|
2024
Q3 | $6.83M | Buy |
59,403
+56,482
| +1,934% | +$6.41M | ﹤0.01% | 3122 |
|
|
2024
Q2 | $311K | Sell |
2,921
-4,094
| -58% | -$411K | ﹤0.01% | 9361 |
|
|
2024
Q1 | $679K | Sell |
7,015
-13,079
| -65% | -$1.34M | ﹤0.01% | 7768 |
|
|
2023
Q4 | $2.03M | Buy |
20,094
+7,485
| +59% | +$722K | ﹤0.01% | 5317 |
|
|
2023
Q3 | $1.28M | Buy |
12,609
+9,139
| +263% | +$928K | ﹤0.01% | 6059 |
|
|
2023
Q2 | $350K | Sell |
3,470
-10,036
| -74% | -$1M | ﹤0.01% | 9127 |
|
|
2023
Q1 | $1.24M | Sell |
13,506
-54,850
| -80% | -$4.79M | ﹤0.01% | 6257 |
|
|
2022
Q4 | $6.2M | Sell |
68,356
-44,137
| -39% | -$3.72M | ﹤0.01% | 2903 |
|
|
2022
Q3 | $8.55M | Buy |
112,493
+34,590
| +44% | +$2.87M | ﹤0.01% | 2383 |
|
|
2022
Q2 | $6.58M | Buy |
77,903
+31,988
| +70% | +$2.81M | ﹤0.01% | 2769 |
|
|
2022
Q1 | $4.03M | Buy |
+45,915
| New | +$3.98M | ﹤0.01% | 4050 |
|
|
2021
Q4 | – | Sell |
-12,083
| Closed | -$1M | – | 13667 |
|
|
2021
Q3 | $988K | Buy |
+12,083
| New | +$1.09M | ﹤0.01% | 7583 |
|
|
2021
Q2 | – | Sell |
-7,711
| Closed | -$687K | – | 13030 |
|
|
2021
Q1 | $659K | Sell |
7,711
-40,984
| -84% | -$3.68M | ﹤0.01% | 8825 |
|
|
2020
Q4 | $4.6M | Buy |
48,695
+43,102
| +771% | +$3.77M | ﹤0.01% | 3544 |
|
|
2020
Q3 | $486K | Buy |
+5,593
| New | +$485K | ﹤0.01% | 7734 |
|
|
2020
Q1 | – | Sell |
-6,378
| Closed | -$569K | – | 10681 |
|
|
2019
Q4 | $604K | Buy |
+6,378
| New | +$572K | ﹤0.01% | 6570 |
|
|
2019
Q3 | – | Sell |
-35,627
| Closed | -$3.2M | – | 10626 |
|
|
2019
Q2 | $3.25M | Buy |
35,627
+24,513
| +221% | +$2.07M | ﹤0.01% | 3324 |
|
|
2019
Q1 | $957K | Buy |
+11,114
| New | +$892K | ﹤0.01% | 5122 |
|
|
2016
Q2 | – | Sell |
-4,648
| Closed | -$321K | – | 9090 |
|
|
2016
Q1 | $302K | Sell |
4,648
-81,689
| -95% | -$5.56M | ﹤0.01% | 7252 |
|
|
2015
Q4 | $6.66M | Buy |
86,337
+68,157
| +375% | +$5.41M | ﹤0.01% | 2181 |
|
|
2015
Q3 | $1.5M | Buy |
18,180
+6,016
| +49% | +$535K | ﹤0.01% | 4879 |
|
|
2015
Q2 | $1.07M | Hold |
12,164
| – | – | ﹤0.01% | 6081 |
|
|
2015
Q1 | $1.07M | Sell |
12,164
-50,769
| -81% | -$4.5M | ﹤0.01% | 5618 |
|
|
2014
Q4 | $5.22M | Buy |
62,933
+37,086
| +143% | +$3.07M | ﹤0.01% | 2818 |
|
|
2014
Q3 | $2.18M | Buy |
+25,847
| New | +$2.09M | ﹤0.01% | 4457 |
|
|
2014
Q2 | – | Sell |
-4,664
| Closed | -$367K | – | 9997 |
|
|
2014
Q1 | $355K | Buy |
4,664
+553
| +13% | +$40.3K | ﹤0.01% | 7324 |
|
|
2013
Q4 | $296K | Buy |
+4,111
| New | +$286K | ﹤0.01% | 7596 |
|
|
2013
Q3 | – | Sell |
-23,843
| Closed | -$1.58M | – | 8654 |
|
|
2013
Q2 | $1.51M | Buy |
+23,843
| New | +$1.55M | ﹤0.01% | 4350 |
|
Other funds holding NVS
Susquehanna International Group's NVS Position: Q1 2026 in Review
Susquehanna International Group reduced its Novartis (NVS) stake by 37% in Q1 2026, selling an estimated $5.41M and leaving 60,281 shares worth $9.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3238.
Susquehanna International Group first reported a position in NVS in Q2 2013 and has held it in 34 quarters since. The position peaked at $32.2M in Q4 2024. 1,596 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Susquehanna International Group held 60,281 shares of Novartis worth $9.21M as of Q1 2026.
- Susquehanna International Group sold 35,284 Novartis shares in Q1 2026, an estimated $5.41M.
- Novartis made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3238 holding.
- Susquehanna International Group first reported a position in Novartis in Q2 2013 and has held it in 34 quarters since.
- Susquehanna International Group's Novartis position peaked at $32.2M in Q4 2024.
- 1,596 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.